N Engl J Med
Olaparib for Metastatic Germline BRCA-Mutated Breast Cancer.
Related Questions
New answer by Medical Oncologist at Mary Lanning Healthcare Morrison Cancer Center/University of Nebraska Medical Center Adjunct Faculty (February 5, 2022)
"Should the preferred adjuvant agent be olaparib or capecitabine or sequential use for germline BRCA1/2 mutated TNBC with residual disease after neoadjuvant chemotherapy?" Res...